Given a document, generate a short title of the document. The title should convey the main idea/event/topic about which the document is being written. Note that URLs in the text have been replaced with [Link].

Example Input: In the end  even Meyer was surprised by what he pulled off.
 "I've gotten myself in trouble before by anointing players before they are deserving of it " he said. "But as far as the defensive front  I don't know if I've ever seen one like this.  In certain areas  I'd have to say it's the best we've ever done."
 NATIONAL PRESENCE: When Meyer arrived in 2005  he said his goal was to primarily recruit regionally. But a strange thing happened over the past five years: Florida has been so successful  it can't help but get recruits from across the country. This year's class has players from seven states other than Florida.
 "My first year in 2005 we went and tried to recruit (nationally)  and we didn't have that brand " Meyer said. "I think with the evolution of the media coverage and the performance of our players  Florida has become a national brand right now. We'll go cherry pick a few for a certain reason."
 BIGGEST NAME: DE Ronald Powell. His presence is significant in many ways  most notably where he's from. Meyer lured Powell from his home that's 90 miles from Southern Cal  then held onto him after Lane Kiffin was hired at USC. Also  Powell is considered the No. 1 player in the nation by several recruiting sites.
 BIGGEST COUP: Tampa Catholic OL Chaz Green. Meyer said the Gators began recruiting Green during his junior year but admits Florida started to fall off the radar with Green during the recruiting process. But assistant coach Dan McCarney refused to give up. And neither would Meyer. "There was about a month when Chaz didn't pick up my phone calls " Meyer said. "Then  bang  all of a sudden he started answering my phone calls.  When he told us he was coming  that was a great day for us because we worked awful hard on that one."
 CLASS SURPRISES: Connecticut QB Tyler Murphy  Atlanta LB Michael Taylor and Homestead LB Darrin Kitchens. With current backup QB Jordan Reed preparing to move to tight end  the Gators needed a backup for John Brantley and early enrollee Trey Burton. They began recruiting Murphy late  and it helped that offensive line coach Steve Addazio was once a classmate of Murphy's father. "He's a freakish athlete with the ball in his hands " Meyer said. As for Taylor  Meyer said  "We were on his radar. He was not on ours. That was our error not to be in the middle of that one." Taylor was MVP for his team in the Under Armour High School All-Star Game at Tropicana Field last month. Kitchens runs a sub-11 100 meters and is a special teams player. "He came up on a visit and kind of stole our heart " Meyer said.
Example Output: MEYER SEES A CLASS WITH POTENTIAL FOR GREATNESS

Example Input: On Friday  Sen. Dianne Feinstein (D-CA) said she will introduce legislation that would raise the minimum age requirements for purchasing a rifle from a gun dealer.
 Feinstein 's declaration comes after 17 people were killed Marjory Stoneman Douglas High School in Parkland  Florida on Wednesday.
 Feinstein 's proposal received a mixed reaction.
I plan to introduce a bill to require ALL firearms purchases from gun dealers be restricted to individuals who are at least 21 years old. If you can’t buy a handgun or a bottle of beer  you shouldn’t be able to buy an AR-15. — Sen Dianne Feinstein (@SenFeinstein) February 17  2018
Example Output: Sen. Feinstein Will Introduce Legislation to Change Minimum Age Requirements for Gun Purchases

Example Input: The drug  called  Kymriah   is a highly personalized cancer treatment called CAR T-cell therapy (CAR is short for chimeric antigen receptor).
The FDA approved  Kymriah  to treat pediatric acute lymphoblastic leukemia in people up to age 25.
The one-time treatment isn't cheap: Novartis  which makes  Kymriah   on Wednesday said the price would be $475 000  which is lower than many expected. Only about 600 people a year could get this treatment  based on Wednesday's approval. Even so  the approval has industry experts and cancer doctors excited.
How  Kymriah  works
 Kymriah  isn't your run-of-the-mill pill â or even a biologic drug  like insulin â that can be mass produced. Since the therapy is made from a person's own immune system  the process can take about three weeks.
While that's a one-time process  it's not the end of the road. About half of the patients in a Kymriah study got cytokine-release syndrome  a response to the reprogrammed cells running loose in the body. It can cause high fevers and flu-like symptoms  and it can be life-threatening. If they get it  patients need to be admitted to intensive-care units  which can bring additional costs. (The FDA on Wednesday expanded the approval of Actemra  a rheumatoid-arthritis drug that can also treat cytokine-release syndrome.)
In a trial of 63 patients treated with Kymriah  83% were in remission after three months  and 64% were still in remission after a year.
Kymriah is the first CAR-T cell therapy to get approved  and several more are in the works. Kite Pharma  Juno Therapeutics  and Bluebird Bio are among a growing group of biotech companies working with CAR-T. Kite  which was recently acquired by Gilead Sciences  is expected to hear back from the FDA about its treatment for aggressive B-cell non-Hodgkin lymphoma by November.
"We're at the very beginning of what's going to be a big new field of medicine " said  David Epstein  who helped license Kymriah from the University of Pennsylvania while at Novartis .
 Epstein  left Novartis in 2016 as CEO of its pharmaceuticals divisions.  He 's now the executive chairman of Rubius Therapeutics  a biotech firm that's also working with cell therapy to develop treatments like  Kymriah  that don't have to be as personalized. The hope is that one day doctors will be able to prescribe a cell therapy and use it that same day instead of waiting weeks to get it back.
 Epstein  said  he  envisioned cell therapies having much shorter life cycles than traditional drugs. Instead of getting a better  updated therapy for a disease every decade or so  we might begin to see second-generation cell therapies in a few years.
Those updates could increase the number of patients that cell therapies can treat. The 600 or so people a year eligible for  Kymriah  now could become tens of thousands  but  it  would require some major changes   Epstein  said.
For one  the treatments would have to treat more types of cancer than the one  Kymriah  was approved for on Wednesday.
And to affect more people  the cell therapies would need to go beyond blood cancers. Right now  that's where most of the big successes have come from  but that could one day include solid tumors and maybe even autoimmune diseases like Type 1 diabetes   Epstein  said.
Example Output:
Why the FDA approved Kymriah  a CAR